Skip to main content

Amyotrophic Lateral Sclerosis (ALS) ATLAS

Status: Closed to Enrollment

Study Details

View study details on www.clinicaltrials.gov.

Locations

  • San Francisco

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

The primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the safety and tolerability tofersen and to evaluate the effect of tofersen on pharmacodynamics (PD)/treatment response biomarkers when initiated prior to versus at the time of emergence of clinically manifest amyotrophic lateral sclerosis (ALS).

Study website: https://www.alsatlasstudy.com/

Jonathan Katz
Jonathan Katz
Principal investigator
View Profile

Co-investigator

Liberty Jenkins

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?